MDAnderson & PALISI: Comprehensive guidelines for paediatric CAR T-cell therapy

The University of Texas MD Anderson Cancer Center News Aug 08, 2018

Almost 1 year after the US Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) have published treatment guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology. These guidelines outline lessons learned by leading...

Go to Original

Paediatrics & Neonatology Oncology Allergy and Immunology

Non loggedin lock

To read this article Sign up / Login for free

This article is only available to members. Are you a doctor? Click here to signup for free.